[go: up one dir, main page]

WO2012018145A3 - Ｑｏｌ改善剤 - Google Patents

Ｑｏｌ改善剤 Download PDF

Info

Publication number
WO2012018145A3
WO2012018145A3 PCT/JP2011/068339 JP2011068339W WO2012018145A3 WO 2012018145 A3 WO2012018145 A3 WO 2012018145A3 JP 2011068339 W JP2011068339 W JP 2011068339W WO 2012018145 A3 WO2012018145 A3 WO 2012018145A3
Authority
WO
WIPO (PCT)
Prior art keywords
life
agent
improving
quality
hepatocellular carcinoma
Prior art date
Application number
PCT/JP2011/068339
Other languages
English (en)
French (fr)
Other versions
WO2012018145A2 (ja
Inventor
光彦 川口
義人 畝
研介 後藤
太乙 郭
喜治 角田
栄一 平野
Original Assignee
株式会社日本生物製剤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社日本生物製剤 filed Critical 株式会社日本生物製剤
Publication of WO2012018145A2 publication Critical patent/WO2012018145A2/ja
Publication of WO2012018145A3 publication Critical patent/WO2012018145A3/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

肝細胞癌患者のＱＯＬ（Ｑｕａｌｉｔｙ　ｏｆ　ｌｉｆｅ）改善剤を提供する。本発明のＱＯＬ改善剤はヒト胎盤抽出物を含有することを特徴とする、肝細胞癌患者のＱＯＬ改善剤であり、特に肝機能改善剤（例えばグリチルリチン酸塩）と併用するのが好ましい。本発明のＱＯＬ改善剤によれば、肝癌細胞を縮小させ、患者の自覚症状を改善し、ＱＯＬを向上させることができるので、末期の肝細胞癌も含め、肝細胞癌の治療において格別な効果をもたらす。
PCT/JP2011/068339 2010-08-05 2011-08-04 Ｑｏｌ改善剤 WO2012018145A2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010-176441 2010-08-05
JP2010176441 2010-08-05

Publications (2)

Publication Number Publication Date
WO2012018145A2 WO2012018145A2 (ja) 2012-02-09
WO2012018145A3 true WO2012018145A3 (ja) 2012-03-29

Family

ID=45559888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2011/068339 WO2012018145A2 (ja) 2010-08-05 2011-08-04 Ｑｏｌ改善剤

Country Status (1)

Country Link
WO (1) WO2012018145A2 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526469A (ja) * 2012-08-20 2015-09-10 ボリス, マルコシアンMarkosian, Boris 癌に対する胎盤ワクチン接種療法
JP2022140106A (ja) * 2021-03-12 2022-09-26 国立大学法人九州大学 プラセンタ抽出物の使用方法
EP4512395A1 (en) * 2023-08-21 2025-02-26 Bio Even Composition comprising flavin adenine dinucleotide (fad), l-gsh, atp and myristic acid, alone or with a drug

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058243A1 (ja) * 2002-12-26 2004-07-15 Ajinomoto Co., Inc. 肝癌発生・進展抑制剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058243A1 (ja) * 2002-12-26 2004-07-15 Ajinomoto Co., Inc. 肝癌発生・進展抑制剤

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HIDEMORI SAKAMOTO ET AL.: "Placenta Chiryo ga Soko shita to Omowareru Tahatsusei Kan Saibo Gan no Ichi Rei", DAI 94 KAI JAPANESE SOCIETY OF GASTROENTEROLOGY KYUSHU SHIBU REIKAI/DAI 88 KAI JAPAN GASTROENTEROLOGICAL ENDOSCOPY SOCIETY KYUSHU SHIBU REIKAI PROGRAM - SHOROKUSHU, 2009, pages 132 *
MAHIKO NAGASE: "Placental therapy", EASTERN MEDICINE, vol. 20, no. 3, 25 February 2005 (2005-02-25), pages 31 - 38 *
NOBUHIRO KAWANO ET AL.: "Remarkable regression of hepatocellular carcinoma by reduced glutathion: A case report", ACTA HEPATOLOGICA JAPONICA, vol. 25, no. 11, 25 November 1984 (1984-11-25), pages 1468 - 1473 *
TATSURO TAKINO ET AL.: "Clinical effects of hepatotherapeutic drugs on chronic liver diseases", JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol. 136, no. 13, 29 March 1986 (1986-03-29), pages 1177 - 1181 *
YASUSHI TSUZUKI: "Taiban Seizai (Melsmon) no Gan Kanja eno Koka ni Tsuite", CLINICAL REPORT, vol. 12, no. 12, November 1978 (1978-11-01), pages 3325 - 3326 *
YUKIO GIBO: "B Gata, C Gata Mansei Kan'en, Kankohen ni Taisuru Kan Higoyaku no Tsukaikata", MEDICINA, vol. 41, no. 10, 10 October 2004 (2004-10-10), pages 1648 - 1650 *

Also Published As

Publication number Publication date
WO2012018145A2 (ja) 2012-02-09

Similar Documents

Publication Publication Date Title
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
WO2013149258A3 (en) Compositions and methods for treating or preventing metabolic syndrome disorders
WO2009152084A3 (en) Adipose tissue-derived stem cells for veterinary use
WO2012014074A3 (en) Motion compensation for non-invasive treatment therapies
WO2011061330A3 (de) Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
WO2008063842A3 (en) Methods of treating neuropathic pain with agonists of ppar-gamma
WO2012012682A3 (en) Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
WO2014058804A3 (en) Micronized compositions composed of bone grafts and methods of making and using the same
WO2012129084A3 (en) Glucosylceramide synthase inhibitors
WO2010102195A3 (en) Annexin a11 and associated genes as biomarkers for cancer
WO2010135692A3 (en) Mirna biomarkers of prostate disease
HK1211231A1 (en) Exendin-4 derivatives
WO2010062863A3 (en) Compositions containing satiogens and methods of use
WO2012050874A3 (en) Targeting heme for the treatment of immune mediated inflammatory diseases
WO2014031859A3 (en) Compositions and methods relating to blood-based biomarkers of breast cancer
WO2012074930A3 (en) Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
IN2014MN02089A (ja)
WO2011011797A3 (en) Cytokine compositions and methods of use thereof
WO2011083464A3 (en) Methods for use of a specific anti-angiogenic adenoviral agent
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
PH12013501902A1 (en) Infant formula for use in the prevention of cardiovascular diseases
WO2012142413A3 (en) Nitrite compositions and uses thereof
IL226386A0 (en) Medical treatment for metabolic syndrome, type 2 diabetes, obesity or pre-diabetes
WO2013117744A3 (en) Methods of treating fibrosis
WO2012053823A3 (ko) 인자 ix 활성을 갖는 융합 단백질

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11814766

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11814766

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: JP